This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

FDA Mulls Easier Access to Cholesterol Drugs

"In our view, given patient monitoring and safety issues, it is unclear whether or not any statins will go OTC," said David R. Risinger of Merrill Lynch. Mevacor will be reviewed in January by the adviser panels on nonprescription drugs and on endocrine and metabolic drugs.

Statins will have a tougher time being converted to nonprescription status than heartburn drugs, such as Prilosec, and antihistamines, such as Claritin, Risinger said. These drugs treat "generally benign conditions," and patients can tell when to start taking the drugs and when to stop, he said. But elevated cholesterol doesn't produce obvious signs, requiring physician monitoring and lab tests. Some statin-linked side-effects can be life-threatening, he added, but "such major adverse events are generally not an issue" with the heartburn drugs and antihistamines.

Risinger said doctors view newer statins as superior to older drugs. Even if Mevacor and Pravachol go OTC, "a majority" of physicians will initially write prescriptions for brand-name drugs "and rarely switch to an OTC unless access is limited by an individual's insurer," he said.

A Different Climate

Bringing up the subject of OTC statins comes at an awkward time, given the continuing scrutiny over the FDA's behavior in such matters as Merck's withdrawal of the arthritis drug Vioxx and Chiron's (CHIR) discovery at literally the last minute that manufacturing problems would kill off its entire supply of flu vaccine for this season.

The agency also has taken criticism for some statins. Baycol was pulled off the market in 2001 by Bayer (BAY) because the drug was linked to some 31 deaths, according to the FDA. The drug, which entered the U.S. market in 1997, had a high rate of the rare muscle-wasting disease called rhabdomyolysis.

In addition, AstraZeneca's (AZN - Get Report) Crestor, approved by the FDA in August 2003, has been criticized by Public Citizen, a U.S. consumer group, and by The Lancet, a leading British medical journal, for what they say are high rates of certain side-effects. Both want the drug withdrawn. AstraZeneca defends Crestor, pointing to clinical trials and comments from top-ranking FDA officials that the drug is safe.
2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AZN $34.05 0.00%
BMY $67.85 0.00%
MRK $53.96 0.00%
PFE $32.79 0.00%
AAPL $117.81 0.00%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs